Search
News & Events
Large-scale study uncovers a single major genetic risk factor for fatal parasitic diseaseResearch has identified a critical genetic risk factor for a potentially fatal parasitic disease that affects up to 400 thousand people a year, mostly children.
News & Events
Infectious Disease & Vaccination Public SeminarHear the facts about vaccination and infectious disease from some of Australia's leading experts: Professor Jonathan Carapetis, Dr Peter Richmond
News & Events
Pneumonia rates improve in Aboriginal childrenNew research from The Kids for Child Health Research shows that the pneumococcal vaccine program has contributed to closing of the gap
News & Events
WANTED: 'Flu BustersHundreds of healthy volunteers are needed in Perth to test the effectiveness of a current 'flu vaccine.
News & Events
Bird flu vaccine produces promising resultsAn Australian-developed vaccine that's been trialed in Perth has been found to produce a strong immune response against the H5N1 bird flu virus.
News & Events
Meningitis study aims for fewer needlesPerth researchers are investigating a new combined vaccine to protect against three causes of potentially deadly bacterial meningitis.
Research
Evaluation of a phased pneumococcal conjugate vaccine introduction in Mongolia using enhanced pneumonia surveillance and community carriage surveysStreptococcus pneumoniae causes substantial morbidity and mortality among children. The introduction of pneumococcal conjugate vaccines (PCV) has the potential to dramatically reduce disease burden. As with any vaccine, it is important to evaluate PCV impact, to help guide decision-making and resource-allocation.
Research
Mandatory vaccination and no fault vaccine injury compensation schemes: An identification of country-level policiesCountries that mandate childhood vaccination without providing no fault compensation schemes could be seen as abrogating the social contract
Research
Assessment of on-time vaccination coverage in population subgroups: A record linkage cohort studyOn-time coverage of the 2-4-6 month schedule is only 50-60% across specific population subgroups representing a significant avoidable public health risk
Research
COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statementThe Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19.